Parkinson's Disease: Treatment
Parkinson's Disease: Overview
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Drugs Affecting Neurotransmitter Synthesis
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Disorders of the Skeletal Muscle
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: May 31, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Feline Hamami1, Jannik Prasuhn2, Leon-Claas van Well3
1Institute of Systems Motor Science, University Medical Center Schleswig-Holstein, University of Lübeck, Lübeck, Germany; Center for Brain, Behavior, and Metabolism, University of Lübeck, Lübeck, Germany.
Functional neurological movement disorders frequently occur alongside dopa-responsive dystonia, significantly increasing patient disability. Early diagnosis is crucial for appropriate treatment, avoiding ineffective L-Dopa increases and guiding physiotherapy.
05:51Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
10:41Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
Published on: September 12, 2020
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: